Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint
Lundbeck A/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China’s National...
OTCMKTS: HLUBF
Lundbeck’s Lu AG13909 Wins Orphan Drug Designations for Congenital Adrenal Hyperplasia
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced that it has received Orphan Drug Designations...
Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia
Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...
Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...
Neuro3 Therapeutics Secures Exclusive License Deal with Lundbeck for KCNQ2 Activator Programs
Neuro3 Therapeutics (Neuro3), a biotechnology company specializing in central nervous system (CNS) diseases with operations...
Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU
Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...